Sun Life U.S. released its annual report analyzing over 70,000 high-cost medical claims, revealing that comorbid conditions, extended hospitalizations, and costly injectable drugs drive claims exceeding $3 million. Common costly conditions include orthopedic/musculoskeletal issues, cancer, and premature infant care, with rising claims linked to obesity-related diseases. The report highlights the growing impact of gene therapies and specialty drugs, like Elevidys for muscular dystrophy, and emphasizes the potential of whole-person care and GLP-1 drugs to reduce high-cost claims. Sun Life also offers health support services and stop-loss insurance to manage these risks and improve outcomes.
Rani Therapeutics Holdings, a clinical-stage biotherapeutics company, announced a registered direct offering of Class A common stock priced at-the-market under Nasdaq rules. The offering includes 12.48 million shares and pre-funded warrants for 6.21 ...
Esperion Therapeutics presented new data at the 2026 European Atherosclerosis Society Congress showing bempedoic acid effectively lowers LDL cholesterol in children aged 6-17 with familial hypercholesterolemia and is well tolerated. A secondary analy...
G. Willi-Food International Ltd. announced a strong first quarter for 2026, with sales increasing by 8.3% to NIS 157 million and gross profit rising 9.7% to NIS 49 million compared to the same period in 2025. Net profit grew by 3% to NIS 20.1 million...
Ituran Location and Control Ltd. announced a $10 million cash dividend for Q1 2026, paying $0.50 per share to shareholders of record on June 24, 2026, with payment on July 8, 2026. The dividend benefits from a reduced 20% tax rate under Israeli tax l...
California Resources Corporation has completed the first CO₂ injection at Carbon TerraVault I, California's first operational carbon capture and storage (CCS) project located in Kern County. This milestone marks a significant step toward California's...
